One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Mineralys Therapeutics, Inc.
MLYS · NMS · Healthcare · Biotechnology
Current price
$16.16
52-week range
$14.91 - $47.00
Market cap
$1.43B
Balance sheet
Healthy
-6,318.67x Concerning
Net cash $526.40M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Return on equity was -68.5% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 0.7% (peer median: 0.8%).
What this company does
Mineralys Therapeutics, Inc.
Mineralys Therapeutics is a company creating new medicines for diseases caused by too much of a hormone called aldosterone, mainly in the United States. Their main product in development is a pill to treat conditions like high blood pressure and kidney problems that are linked to this hormone imbalance, which matters because these are common and serious health issues.
How Mineralys Therapeutics Came To Be
Mineralys Therapeutics was founded in 2019 with a specific mission: to develop treatments for diseases caused by an imbalance of a hormone called aldosterone. In 2020, the company licensed a promising drug candidate, lorundrostat, from Mitsubishi Tanabe Pharmaceutical Company, which had already completed early-stage research on it. This move was pivotal, setting Mineralys on a path to focus intensely on this particular area of medicine. The company's journey has involved significant fundraising, including a successful initial public offering (IPO) in 2023, which provided the capital needed to advance its research and development efforts. Mineralys is now a publicly traded company, aiming to bring its targeted therapy to patients.
What Mineralys Therapeutics Actually Does
Mineralys Therapeutics is a biopharmaceutical company that focuses on creating new medicines. Their main goal is to develop treatments for conditions linked to too much aldosterone, a hormone that plays a key role in regulating blood pressure. The company's primary focus is on a drug called lorundrostat, which is designed to target the root cause of these aldosterone-related issues. They are currently conducting clinical trials to test the safety and effectiveness of lorundrostat in patients with specific health problems.
Lorundrostat for Hypertension and Cardiorenal Conditions
Mineralys Therapeutics' core business revolves around its single lead drug candidate, lorundrostat. This drug is being developed as a highly selective aldosterone synthase inhibitor, meaning it targets an enzyme responsible for producing aldosterone. The company is initially focusing on treating uncontrolled or resistant hypertension (high blood pressure that doesn't respond well to other treatments). Beyond hypertension, Mineralys is also investigating lorundrostat's potential in treating related conditions like chronic kidney disease (CKD) and obstructive sleep apnea (OSA), which are also influenced by aldosterone levels. The company is investing heavily in clinical trials to prove lorundrostat's effectiveness and safety across these different conditions.
Management's Current Strategy
Mineralys Therapeutics' management is betting on the success of lorundrostat as a targeted therapy for aldosterone-driven diseases. Their strategy involves rigorously proving the drug's efficacy and safety through late-stage clinical trials, particularly in patients with difficult-to-treat hypertension. They are also exploring the drug's potential in other cardiorenal conditions, such as chronic kidney disease. The company's focus is on advancing lorundrostat through the regulatory approval process and preparing for its potential commercialization. This strategy relies on demonstrating a clear benefit for patients who have limited treatment options.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q4
$-66.84M
FY2025 Q1
$-45.49M
FY2025 Q2
$-30.17M
FY2025 Q3
$-28.87M
FY2025 Q4
$-37.90M
Revenue
—
Net income
$-57.33M
Diluted EPS
-0.64
Operating cash flow
$-43.10M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-241.07M
Diluted EPS
-2.85
Operating cash flow
$-32.56M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-39.34M
Diluted EPS
-0.47
Operating cash flow
$-39.47M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-32.23M
Diluted EPS
-0.32
Operating cash flow
$-37.89M
Free cash flow
$-37.90M
Fetching…
Sources
Revenue
—
Net income
$-36.93M
Diluted EPS
-0.52
Operating cash flow
$-28.87M
Free cash flow
$-28.87M
Fetching…
Sources
Revenue
—
Net income
$-43.27M
Diluted EPS
-0.66
Operating cash flow
$-30.17M
Free cash flow
$-30.17M
Fetching…
Sources
Revenue
—
Net income
$-42.21M
Diluted EPS
-0.79
Operating cash flow
$-45.49M
Free cash flow
$-45.49M
Fetching…
Sources
Revenue
—
Net income
$-48.95M
Diluted EPS
-1.00
Operating cash flow
$-66.84M
Free cash flow
$-66.84M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $16.16
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $526.4M - more cash than debt. Interest coverage -6318.7x.
Net debt
$-526.40M
Interest coverage
-6,318.67x
Mineralys Therapeutics, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
MLYS
BASELINE
Mineralys Therapeutics, Inc.
Total debt $98.27M Interest coverage -6,318.67x This is the baseline the peer rows are being compared against.
Total debt $1.43B Interest coverage -5.89x Neither company has much profit cushion over interest right now.
Total debt $283.55M Interest coverage -1.44x Neither company has much profit cushion over interest right now.
Total debt $2.85M Interest coverage -34.80x Neither company has much profit cushion over interest right now.
Total debt $59.54M Interest coverage -5.87x Neither company has much profit cushion over interest right now.
What you should know
The case for and against MLYS
0 Rewards
2 Risks
Rewards
Risks
-
Return on equity was -68.5% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 0.7% (peer median: 0.8%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-6.20x
P/B
2.84x
P/S
—
EV/EBITDA
-2.32x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-68.5%
ROA
-39.6%
Health
Liquidity and balance-sheet strength
Debt / equity
0.20x
Current ratio
11.83x
Quick ratio
11.77x
Total debt
$98.27M
Total cash
$624.67M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-4.30
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-153.01M
Free CF TTM
$-142.43M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—